Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
MATCH Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations Excluding Melanoma and Thyroid Cancer
Study Type: Treatment
Phase: II
NCTID: NCT02465060
Principal Investigator:
Benjamin Powers
A Phase I/II, open-label study of PD-1 knockout tumor-infiltrating lymphocytes IOV-4001 in participants with unresectable or metastatic melanoma or Stage III or IV non-small-cell lung cancer
A PHASE II RANDOMIZED STUDY OF NIVOLUMAB (NSC-748726) WITH IPILIMUMAB (NSC-732442) OR IPILIMUMAB ALONE IN ADVANCED MELANOMA PATIENTS REFRACTORY TO AN ANTI-PD1 OR ANTI-PD-L1 AGENT
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, a Phase III Trial
A Phase III Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA A02:01-Positive Participants With Previously Untreated Advanced Melanoma PRISM-MEL-301
Study Type: Treatment
Phase: III
NCTID: NCT06112314
Principal Investigator:
Gary Doolittle
Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion before Tumor-Infiltrating Lymphocyte Therapy with Lifileucel in Metastatic Melanoma
Study Type: Treatment
Phase: II
NCTID: NCT06151847
Principal Investigator:
Muhammad Umair Mushtaq
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon alpha-2b for Resected High-Risk Melanoma.
A Phase III, Multicenter, Randomized, Open-label, Parallel group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel LN-144, Autologous Tumor-infiltrating Lymphocytes [TIL] Regimen in Combination with Pembrolizumab Compared with Pembrolizumab Monotherapy in Participants with Untreated, Unresectable or Metastatic Melanoma
A Randomized, Controlled, Multicenter, Phase III Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician?s Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen
Study Type: Treatment
Phase: III
NCTID: NCT06264180
Principal Investigator:
Gary Doolittle